ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅.
Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅ ΠΈ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΡ Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΠΏΠ»Π°Π·ΠΈΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ (ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ)
Kleinberg DL, Ruan W, Yee D, Kovacs KT, Vidal S. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice. // Endocrinol. 2007. Vol.148, N 3. P. 1080β1088. Bastard J-P, Maachi M, Lagathu C, Claire Lagathu, Min Ji Kim, Martine Caron, Hubert Vidal, Jacqueline Capeau, Bruno Feve. Recent… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅ ΠΈ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΡ Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΠΏΠ»Π°Π·ΠΈΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ (ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ) (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
ΠΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Π³ΠΎ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΡ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΡΡΠΈΡΠ°ΡΡ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅ΠΏΡΠΈΠΈ ΡΠΎΠ»ΠΈ Π‘Π ΠΈ ΠΠ , ΠΊΠ°ΠΊ ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΌΠ½ΠΎΠ³ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ, ΠΠΠΠ [2]. ΠΠ½Π° ΠΎΠ±ΡΠ΅Π΄ΠΈΠ½ΡΠ΅Ρ ΡΠΌΠΏΠΈΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π°ΠΉΠ΄Π΅Π½Π½ΡΠ΅ ΡΠ°ΠΊΡΡ ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΈ ΡΠ΅Π³ΡΠ΅ΡΡ ΠΠΠΠ ΡΠ΅Π³ΡΠ»ΡΡΠ½ΠΎΠΉ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π°Π³ΡΡΠ·ΠΊΠΈ [7], Π΄ΠΈΠ΅ΡΡ Ρ Π½ΠΈΠ·ΠΊΠΈΠΌ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ΠΌ Π½Π°ΡΡΡΠ΅Π½Π½ΡΡ ΠΈ ΠΎΠΊΠΈΡΠ»Π΅Π½Π½ΡΡ ΠΆΠΈΡΠ½ΡΡ ΠΊΠΈΡΠ»ΠΎΡ [44], ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΡΠ³Π»Π΅Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° [45], Π±ΠΎΡΡΠ±Ρ Ρ ΡΠΌΠΎΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΌ ΡΡΡΠ΅ΡΡΠΎΠΌ [46] ΠΈ ΠΎΡΠΊΡΡΠ²Π°Π΅Ρ Π½ΠΎΠ²ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΠΎΠΈΡΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΡΠ΅Π΄ΡΡΠ², ΠΏΠΎΠ΄Π°Π²Π»ΡΡΡΠΈΡ Π‘Π ΠΈ ΠΠ . ΠΠ½Π°Π»ΠΈΠ·ΠΈΡΡΡ ΠΏΠ°ΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎ ΠΠΠΠ, ΠΊΠ°ΠΊ ΡΠ»Π΅Π΄ΡΡΠ²ΠΈΡ Π°Π½Π΄ΡΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ Π΄Π΅ΡΠΈΡΠΈΡΠ°, Π. Π. Π’ΡΠ·ΠΈΠΊΠΎΠ² ΡΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π½Π° ΡΠ²ΡΠ·Ρ ΡΡΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° Ρ ΠΎΠ±ΡΠΈΠΌ Π΄ΠΈΡΠ³ΠΎΡΠΌΠΎΠ½Π°Π»ΡΠ½ΡΠΌ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ΠΌ ΠΈ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅ΠΌ [47]. Π ΡΡΠΎΠΌ ΠΏΠ»Π°Π½Π΅ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΡ Π½Π΅ΠΌΠ½ΠΎΠ³ΠΎΡΠΈΡΠ»Π΅Π½Π½ΡΠ΅ ΠΏΠΎΠΊΠ° ΠΏΠΎΠΏΡΡΠΊΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠ° ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ, Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΡ Π½Π° ΠΏΠΎΠ΄Π°Π²Π»Π΅Π½ΠΈΠ΅ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ.
ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- 1. Π’ΡΠ·ΠΈΠΊΠΎΠ² Π. Π. ΠΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ Π°Π½Π΄ΡΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ Π΄Π΅ΡΠΈΡΠΈΡΠ° ΠΈ ΡΡΠΎΠ½Π΅ΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΏΠΎΡΠ΅ΠΊ Ρ ΠΌΡΠΆΡΠΈΠ½ (Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΠΉ ΠΎΠ±Π·ΠΎΡ). // Π£ΡΠΎΠ»ΠΎΠ³ΠΈΡ ΠΈ Π³Π΅Π½ΠΈΡΠ°Π»ΡΠ½Π°Ρ Ρ ΠΈΡΡΡΠ³ΠΈΡ 2012, № 4, Π‘. 3−12.
- 2. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. // Indian J Urol. 2014. Vol. 30, N 2, P.170−176.
- 3. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: Clinical connections, emerging etiological paradigms and future directions. // J Urol. 2013. Vol. 189, N 1, Supplement. P. 102−106.
- 4. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. ?e correlation between metabolic syndrome and prostatic diseases. // Eur Urol 2012. Vol. 61, N 3. P. 560−70.
- 5. SarmaAV, ParsonsJK, McVaryK, WeiJT. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms — What do we know? // J Urol 2009, Vol. 182, N 6, Supplement. P. 32−37.
- 6. Joseph MA, Harlow SD, Wei JT. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. // Am J Epidemiol 2003, Vol. 157. P. 906−14.
- 7. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. // Eur Urol. 2008. Vol. 53. Π . 1228−1235.
- 8. Π Π°ΡΠΈΠ½ Π. Π‘., ΠΠ°ΠΉΠ΄Π°ΡΠ΅Π² Π. Π. Π ΠΎΠ»Ρ ΡΠ΄Π΅ΡΠ½ΡΡ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΠΎΠ½Π½ΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ² Π² ΡΠΈΠ½ΡΡΠΎΠΏΠΈΠΈ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ Π²Π½ΡΡΡΠ΅Π½Π½Π΅ΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. ΠΠΎΠ²ΡΠΉ Π²Π·Π³Π»ΡΠ΄ Π½Π° ΡΡΠ°ΡΡΠ΅ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ.// Π£ΠΊΡ ΠΌΠ΅Π΄ ΠΆΡΡΠ½Π°Π». 2014. N 1(99)I.
- 9. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the ird National Health and Nutrition Examination Survey (NHANES III). // Prostate. 2005. Vol. 62, N1. Π . 27−33.
- 10. Tian R, Hou G, Li D, Yuan TF. A possible change process of inflammatory cytokines in the prolonged chronic stress and its ultimate implications for health. // Scientific World Journal. 2014. Vol. 2014, Article ID 780 616 .
- 11. Rohleder N. Stimulation of systemic low-grade inflammation by psychosocial stress. // Psychosom Med. 2014. Vol. 76, N 3, P.181−189.
- 12. ΠΠ°ΠΉΠ΄Π°ΡΠ΅Π² Π. Π. NF-kB-ΡΠΈΠ³Π½Π°Π»ΠΈΠ·Π°ΡΠΈΡ ΠΊΠ°ΠΊ ΠΎΡΠ½ΠΎΠ²Π° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ, ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ, Π»ΠΈΠΏΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ, ΡΠ°Ρ Π°ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°Π±Π΅ΡΠ° 2-Π³ΠΎ ΡΠΈΠΏΠ° ΠΈ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ·Π°. // ΠΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠΉ ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π». 2011. Π’.3, N 35, Π‘. 35−40.
- 13. Miller G E, Chen E, Sze J. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-ΠΊB signaling. // Biological Psychiatry. 2008. Vol. 64, N 4. P. 266−272.
- 14. Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. // Trends Pharmacol Sci. 2013, Vol. 34, N 9. P. 518−530.
- 15. Ramamoorthy S, Cidlowski JA. Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance. // Endocr Dev. 2013. Vol. 24, N 41. P. 56−64.
- 16. Calcagni E, Elenkov I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. // Ann N Y Acad Sci. 2006. N 1069. P. 62−76.
- 17. Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. // J leukocyte biol. 2005. Vol. 78, N 4. P. 819−35.
- 18. Febbraio MA, Pedersen BK. Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? // Exerc Sport Sci Rev. 2005. Vol. 33, N 3. P. 114−119.
- 19. Calder PC, Kew S. The immune system: a target for functional foods? // Br J Nutr. 2002. Vol. 88, Suppl. 2. P. 165−177.
- 20. Salmeron J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willett WC. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women.// JAMA. 1997. Vol. 277, N 6. P. 472−477.
- 21. Bastard J-P, Maachi M, Lagathu C, Claire Lagathu, Min Ji Kim, Martine Caron, Hubert Vidal, Jacqueline Capeau, Bruno Feve. Recent advances in the relationship between obesity, inflammation, and insulin resistance. // Eur Cytokine Netw. 2006. Vol. 17, N 1. P. 4−12.
- 22. Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. // Trends Endocrinol Metab. 2012. Vol. 23, N 7. P. 351−363.
- 23. DeFronzo R, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. // Am J Physiol. 1979, Vol. 237, N 3. P. 214−223.
- 24. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, SchrΡder F, Sciarra A, Tubaro A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. // Eur Urol. 2011. Vol. 60. P. 106−117.
- 25. Stroup SP, Palazzi-ChurasK, KoppRP, ParsonsJK. Trendsin adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. // BJU Int. 2012. Vol. 109, N 1. P. 84−87.
- 26. Fong YK, Milani S, Djavan B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. // Curr Opin Urol. 2005. Vol. 15, N 1. P. 35−38.
- 27. Shenk J.M., Kristal A.P., Neuhouser M.L., Catherine M Tangen, Emily White, Daniel W Lin. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. // Am J Epidemiol. 2010. Vol. 171, N 5. P. 571−82
- 28. Jennifer L. St. Sauver, Aruna V. Sarma, Debra J. Jacobson, Michaela E. McGree, Michael M. Lieber, Cynthia J. Girman, Ajay Nehra, and Steven J. Jacobsen. Associations between Creactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort.// Am J Epidemiol. 2009. Vol.169, N 11. P. 1281−1290.
- 29. Kristal AR, Arnold KB, Henk JM. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. // J Urol. 2007. Vol.177, N 4. P.1395−1400.
- 30. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, SchrΡder F, Sciarra A, Tubaro A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. // Eur Urol. 2011. Vol. 60, N 1. P. 106−117.
- 31. Ganpule AP, Desai MR, Desai MM. Natural history of lower urinary tract symptoms: Preliminary report from a community-based Indian study. // BJU Int. 2004. Vol. 94. P. 332−334.
- 32. Stamatiou K, Lardas M, Kostakos E, Koutsonasios V, Michail E. ?e impact of diabetes type 2 in the pathogenesis of benign prostatic hyperplasia // Adv Urol. 2009. Article ID 818 965.
- 33. Kleinberg DL, Ruan W, Yee D, Kovacs KT, Vidal S. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice. // Endocrinol. 2007. Vol.148, N 3. P. 1080−1088.
- 34. Rahman NU, Phonsombat S, Bochinski D, Rafael E. Carrion, Lora Nunes and Tom F. Lue. An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. // BJU Int. 2007. Vol. 100, N 3, P. 658−663.
- 35. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. // BJU Int. 1999. Vol. 84, N 9. P.976−981.
- 36. Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL. Risk factors for lower urinary tractsymptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: The Krimpen study.// J Urol. 2009. Vol. 181, N 2. P. 710−716.
- 37. Astrup A. Book Review. The Metabolic Syndrome: Epidemiology, Clinical Treatment, and Underlying Mechanisms. // New Engl J Med. 2008. Vol. 359, N 3. P. 322−25.
- 38. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview.// Clin Sci (Lond). 2012. Vol. 122, N 6. P. 253−270
- 39. Xiao, Xingyuan, Wang, Zongwei; Olumi, Aria F. Metformin regulates the proliferation of prostate epithelial cells inhibition of Insulin-like growth factor 1 receptor.//. AUA University. Session Title: Benign Prostatic Hyperplasia: Basic ResearΡh. 2012. Poster Abstract: 1567 URL: https://www.auanet.org/University/abstract_detail.cfm?id=1567&meetingID=12ATL
- 40. Chin-Hsiao Tseng. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. Tseng // BMC Cancer. 2013 Vol.13. P.7.
- 41. Murff HJ, Roumie CL, Greevy RA, Grijalva CG, Hung AH, Liu X, Griffin MR. ?iazolidinedione and Metformin use and the risk of benign prostate hyperplasia in veterans with diabetes mellitus.// J Mens Health. 2014. Vol. 11, N 4. P.157−162.
- 42. Vikram A, Jena G, Ramarao P. Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. // Br J Pharmacol. 2010 Vol.161, N 8. P.1708−1721.
- 43. Schernthaner G, Currie CJ, Schernthaner GH. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. // Diabetes Care. 2013. Vol. 36, Suppl. 2. P.155−161.
- 44. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, ?ompson IM. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial. // Am J Epidemiol. 2008. Vol.167, N 8. P. 925−934.
- 45. Sarma AV, St Sauver JL, Hollingsworth JM, Jacobson DJ, McGree ME, Dunn RL, Lieber MM, Jacobsen SJ Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men. // Urology. 2012. Vol.79, N 1. P.102−107.
- 46. Ullrich PM, Lutgendorf SK, Leserman J, Turesky DG, Kreder KJ. Stress, hostility, and disease parameters of benign prostatic hyperplasia. // Psychosom Med. 2005. Vol. 67, N3. P.476−482.
- 47. Π’ΡΠ·ΠΈΠΊΠΎΠ² Π. Π., ΠΠ°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΠΎΡΠ΅ΠΊ ΠΊΠ°ΠΊ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ «ΠΌΠ°ΡΠΊΠ°» Π°Π½Π΄ΡΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ Π΄Π΅ΡΠΈΡΠΈΡΠ° Ρ ΠΌΡΠΆΡΠΈΠ½. ΠΠ΅ΠΊΡΠΈΡ. ΠΠΠ"ΠΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠΉ ΡΠ΅Π½ΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ-ΠΏΠ»ΡΡ", Π³. Π―ΡΠΎΡΠ»Π°Π²Π»Ρ. 30 ΠΌΠ°ΡΡΠ° 2013 Π³ΠΎΠ΄Π°. // URL: http://vestnik.rncrr.ru/vestnik/v13/papers/tyuzikov_v13.htm